167113-73-7

Basic information

• Product Name: 1,2-Cyclopropanedicarboxylicacid,monoethylester(9CI)
• Synonyms: 1,2-Cyclopropanedicarboxylicacid,monoethylester(9CI);2-(Ethoxycarbonyl)cyclopropane-1-carboxylic acid;Ethyl 2-carboxycyclopropane-1-carboxylate;1,2-Cyclopropanedicarboxylic acid 1-ethyl ester
• CAS NO: 167113-73-7
• Molecular Formula: C₇H₁₀O₄
• Molecular Weight: 158.1519
• Product Categories: CARBOXYLICACID
• Mol File: 167113-73-7.mol

Chemical Properties

• Boiling Point: 266.8 °C at 760 mmHg
• Flash Point: 109.6 °C
• Appearance: /
• Density: 1.322 g/cm³
• CAS DataBase Reference: 1,2-Cyclopropanedicarboxylicacid,monoethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Cyclopropanedicarboxylicacid,monoethylester(9CI)(167113-73-7)
• EPA Substance Registry System: 1,2-Cyclopropanedicarboxylicacid,monoethylester(9CI)(167113-73-7)

Safety Data

• Hazardous Substances Data: 167113-73-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
1,2-Cyclopropanedicarboxylic acid, monoethylester (9CI) is used as a building block for various chemical synthesis processes. Its cyclopropane ring and ester group provide a foundation for creating a wide range of chemical products, including pharmaceuticals, agrochemicals, and specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,2-Cyclopropanedicarboxylic acid, monoethylester (9CI) is used as a key intermediate in the synthesis of various drug molecules. Its unique structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Agrochemical Industry:
1,2-Cyclopropanedicarboxylic acid, monoethylester (9CI) is also utilized in the agrochemical industry for the synthesis of novel pesticides and other crop protection agents. Its incorporation into these products can lead to enhanced performance and reduced environmental impact.
Used in Specialty Chemicals:
In the specialty chemicals sector, 1,2-Cyclopropanedicarboxylic acid, monoethylester (9CI) is employed in the development of high-performance materials, such as advanced polymers and coatings. Its unique properties contribute to the creation of innovative products with improved characteristics and applications.

Upstream product

• 20561-09-5 diethyl (cis,trans)-1,2-cyclopropanedicarboxylate 
• 13949-93-4 ethyl-2-formyl-1-cyclopropane carboxylate 

Downstream Products

• 194206-09-2 methyl N^α-[(1-benzyloxycarbonylindolin-5-yl)carbonyl]-N^δ-[2-(ethoxycarbonyl)cyclopropylcarbonyl]-L-ornithinate 
• 1055036-70-8 2-((S)-4-Benzyloxycarbonylamino-4-carboxy-butylcarbamoyl)-cyclopropanecarboxylic acid ethyl ester 
• 194206-02-5 methyl N^α-benzyloxycarbonyl-N^δ-[2-(ethoxycarbonyl)cyclopropylcarbonyl]-L-orthinate 
• 178687-20-2 2-chlorocarbonyl-cyclopropanecarboxylic acid ethyl ester 

Relevant articles and documents

USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS

A medicament for treating or preventing pruritus is provided. For the medicament for treating or preventing pruritus, a compound having a blocking action on Cav3.2T-type calcium channels represented by General Formulas (I) to (VI), a tautomer of the compo

Halothenoyl-cyclopropane-1-carboxylic acid derivatives

Compounds of formula (I) wherein R is hydroxy, linear or branched C1-C6 alkoxy, phenoxy, benzyloxy, a group -N(R1R2) wherein R1 is hydrogen, linear or branched C1-C4 alkyl, benzy

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the formula STR1 for example STR2

Substituted β-amino acid derivatives useful as platelet aggregation inhibitors

Novel substituted β amino acid derivatives are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

Substituted heterocyclic derivatives useful as platelet aggregation inhibitors

Novel substituted heterocyclic derivatives are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

Antibacterial agents, and 4-thio azetidinone intermediates

This invention relates to 2-substituted and 2,6-disubstituted penem compounds of the formula STR1 wherein Y is hydrogen, halo or certain organic substituents and X represents certain organic substituents. Also included in the invention are pharmaceutically acceptable salts of the above compounds and derivatives of the above compounds in which the carboxyl group at the 3-position is protected as by an easily removable ester protecting group. The compounds of the present invention are potent antibacterial agents or are of use as intermediates in the preparation of such agents.